|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.905 USD | -0.78% |
|
-1.51% | +23.28% |
CytomX Therapeutics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was USD 53.16 million compared to USD 37.31 million a year ago. Net loss was USD 99.32 million compared to USD 115.87 million a year ago.
Basic loss per share from continuing operations was USD 1.51 compared to USD 1.81 a year ago. Diluted loss per share from continuing operations was USD 1.51 compared to USD 1.81 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +23.28% | 150M | |
| +9.48% | 115B | |
| +12.84% | 107B | |
| -13.73% | 22.31B | |
| -3.46% | 21.6B | |
| -4.84% | 18.23B | |
| -38.57% | 17.62B | |
| +7.25% | 14.26B | |
| +34.95% | 12.37B | |
| -26.21% | 8.28B |
CYTOMX THERAPEUTICS, INC. 